McLellan Lab

About The McLellan Lab

The human body is under constant attack from bacteria, fungi, parasites, and viruses, all of which express proteins that are needed to establish infection and evade the human immune system. The McLellan Lab seeks to obtain structural information on these proteins and their interactions with host macromolecules and translate this knowledge into the rational development of therapeutic interventions such as small-molecule inhibitors, protective antibodies and stabilized vaccine immunogens. These efforts are highly collaborative and involve domestic and international investigators from academia, government, and industry. The McLellan Lab focuses on the following:

• Coronaviridae: Coronoviruses, such as SARS-CoV and MERS-CoV, are an important element of the McLellan Lab's research. One of their main goals is to provide a unifying structural framework for the function of coronavirus spike (S) proteins, including the mechanisms of receptor-induced triggering of membrane fusion. They are also leveraging the structural and mechanistic information to develop broadly protective antibodies and vaccines to combat current and emerging pathogenic coronaviruses.

• Pneumoviridae: Understanding the entry process of Pneumoviruses, such as human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV), into host cells at a molecular level is another major focus of their work. They also have on-going projects involving structure-based vaccine design, antibody isolation and characterization, and development of next-generation small-molecule fusion inhibitors.

2023 Research

• Goike J, Hsieh CL, Horton AP, Gardner EC, Zhou L, Bartzoka F, Wang N, Javanmardi K, Herbert A, Abbassi S, Xie X, Xia H, Shi PY, Renberg R, Segall- Shapiro TH, Terrace CI, Wu W, Shroff R, Byrom M, Ellington AD, Marcotte EM, Musser JM, Kuchipudi SV, Kapur V, Georgiou G, Weaver SC, Dye JM, Boutz DR, McLellan JS, Gollihar JD. SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode. Commun Biol. 2023 Dec 11;6(1):1250. PMID: 38082099; PMCID: PMC10713552.

• Zehner M, Alt M, Ashurov A, Goldsmith JA, Spies R, Weiler N, Lerma J, Gieselmann L, Stöhr D, Gruell H, Schultz EP, Kreer C, Schlachter L, Janicki H, Laib Sampaio K, Stegmann C, Nemetchek MD, Dähling S, Ullrich L, Dittmer U, Witzke O, Koch M, Ryckman BJ, Lotfi R, McLellan JS, Krawczyk A, Sinzger C, Klein F. Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer. Immunity. 2023 Nov 14;56(11):2602-2620.e10.10.009. PMID: 37967532.

• Yu X, Abeywickrema P, Bonneux B, Behera I, Anson B, Jacoby E, Fung A, Adhikary S, Bhaumik A, Carbajo RJ, De Bruyn S, Miller R, Patrick A, Pham Q, Piassek M, Verheyen N, Shareef A, Sutto-Ortiz P, Ysebaert N, Van Vlijmen H, Jonckers THM, Herschke F, McLellan JS, Decroly E, Fearns R, Grosse S, Roymans D, Sharma S, Rigaux P, Jin Z. Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor. Commun Biol. 2023 Oct 21;6(1):1074. PMID: 37865687; PMCID: PMC10590419.

• Hutchinson GB, Abiona OM, Ziwawo CT, Werner AP, Ellis D, Tsybovsky Y, Leist SR, Palandjian C, West A, Fritch EJ, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan JS, Baric RS, King NP, Graham BS, Corbett-Helaire KS. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera. Nat Commun. 2023 Oct 4;14(1):6195. PMID: 37794071; PMCID: PMC10551005.

• Tse LV, Hou YJ, McFadden E, Lee RE, Scobey TD, Leist SR, Martinez DR, Meganck RM, Schäfer A, Yount BL, Mascenik T, Powers JM, Randell SH, Zhang Y, Wang L, Mascola J, McLellan JS, Baric RS. A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus. Sci Transl Med. 2023 Sep 27;15(715):eadg5567. Epub 2023 Sep 27. PMID: 37756379.

• McCool RS, Musayev M, Bush SM, Derrien-Colemyn A, Acreman CM, Wrapp D, Ruckwardt TJ, Graham BS, Mascola JR, McLellan JS. Vaccination with prefusion- stabilized respiratory syncytial virus fusion protein elicits antibodies targeting a membrane-proximal epitope. J Virol. 2023 Sep 22;97(10):e0092923. Epub ahead of print. PMID: 37737588; PMCID: PMC10617438.

• McNamara RP, Maron JS, Boucau J, Roy V, Webb NE, Bertera HL, Barczak AK, Positives Study Staff T, Franko N, Logue JK, Kemp M, Li JZ, Zhou L, Hsieh CL, McLellan JS, Siedner MJ, Seaman MS, Lemieux JE, Chu HY, Alter G. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern. mBio. 2023 Aug 3:e0090223. Epub ahead of print. PMID: 37535402.

• Osickova A, Knoblochova S, Bumba L, Man P, Kalaninova Z, Lepesheva A, Jurnecka D, Cizkova M, Biedermannova L, Goldsmith JA, Maynard JA, McLellan JS, Osicka R, Sebo P, Masin J. A conserved tryptophan in the acylated segment of RTX toxins controls their β2 integrin-independent cell penetration. J Biol Chem. 2023 Jun 28;299(8):104978. Epub ahead of print. PMID: 37390987; PMCID: PMC10392135.

• Cable J, Graham BS, Koup RA, Seder RA, Karikó K, Pardi N, Barouch DH, Sharma B, Rauch S, Nachbagauer R, Forsell MNE, Schotsaert M, Ellebedy AH, Loré K, Irvine DJ, Pilkington E, Tahtinen S, Thompson EA, Feraoun Y, King NP, Saunders K, Alter G, Moin SM, Sliepen K, Karlsson Hedestam GB, Wardemann H, Pulendran B, Doria-Rose NA, He WT, Juno JA, Ataca S, Wheatley AK, McLellan JS, Walker LM, Lederhofer J, Lindesmith LC, Wille H, Hotez PJ, Bekker LG. Progress in vaccine development for infectious diseases-a Keystone Symposia report. Ann N Y Acad Sci. 2023 Apr 5. Epub ahead of print. PMID: 37020354.

• Goldsmith JA, Dewar V, Hermand P, Blais N, McLellan JS. Structural Basis for Binding of Neutralizing Antibodies to Clostridioides difficile Binary Toxin. J Bacteriol. 2023 Apr 25;205(4):e0045622. Epub 2023 Mar 23. PMID: 36951574; PMCID: PMC10127577.

• Silva RP, Huang Y, Nguyen AW, Hsieh CL, Olaluwoye OS, Kaoud TS, Wilen RE, Qerqez AN, Park JG, Khalil AM, Azouz LR, Le KC, Bohanon AL, DiVenere AM, Liu Y, Lee AG, Amengor DA, Shoemaker SR, Costello SM, Padlan EA, Marqusee S, Martinez- Sobrido L, Dalby KN, D'Arcy S, McLellan JS, Maynard JA. Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses. Elife. 2023 Mar 21;12:e83710. PMID: 36942851; PMCID: PMC10030117.

• Byrne PO, Fisher BE, Ambrozak DR, Blade EG, Tsybovsky Y, Graham BS, McLellan JS, Loomis RJ. Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein. Nat Commun. 2023 Mar 17;14(1):1494. PMID: 36932063; PMCID: PMC10021056.

• Jenks JA, Amin S, Sponholtz MR, Kumar A, Wrapp D, Venkatayogi S, Tu JJ, Karthigeyan K, Valencia SM, Connors M, Harnois MJ, Hora B, Rochat E, McLellan JS, Wiehe K, Permar SR. A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. PLoS Pathog. 2023 Jan 20;19(1):e1011107. PMID: 36662906; PMCID: PMC9891502.

2022 Research

• Li L, Wen Y, Wrapp D, Jeong J, Zhao P, Xiong W, Atkins CL, Shan Z, Hui D, McLellan JS, Zhang N, Ju C, An Z. A novel humanized Chi3l1 blocking antibody attenuates acetaminophen-induced liver injury in mice. Antib Ther. 2022 Nov 7;6(1):1-12. PMID: 36683763; PMCID: PMC9847341.

• Hutchinson G, Abiona O, Ziwawo C, Werner A, Ellis D, Tsybovsky Y, Leist S, Palandjian C, West A, Fritch E, Wang N, Wrapp D, Boyoglu-Barnum S, Ueda G, Baker D, Kanekiyo M, McLellan J, Baric R, King N, Graham B, Corbett K. Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive protection across divergent subgroups. Res Sq [Preprint]. 2022 Nov 7:rs.3.rs-2199814. PMID: 36380759; PMCID: PMC9645427.

• Stephens LM, Ross KA, McLellan JS, Narasimhan B, Varga SM. Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model. J Virol. 2022 Nov 23;96(22):e0150222. Epub 2022 Oct 31. PMID: 36314826; PMCID: PMC9683007.

• Chang MR, Tomasovic L, Kuzmina NA, Ronk AJ, Byrne PO, Johnson R, Storm N, Olmedillas E, Hou YJ, Schäfer A, Leist SR, Tse LV, Ke H, Coherd C, Nguyen K, Kamkaew M, Honko A, Zhu Q, Alter G, Saphire EO, McLellan JS, Griffiths A, Baric RS, Bukreyev A, Marasco WA. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat Commun. 2022 Oct 3;13(1):5814. PMID: 36192374; PMCID: PMC9528872.

• Rush SA, Brar G, Hsieh CL, Chautard E, Rainho-Tomko JN, Slade CD, Bricault CA, Kume A, Kearns J, Groppo R, Mundle ST, Zhang L, Casimiro D, Fu TM, DiNapoli JM, McLellan JS. Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus. Cell Rep. 2022 Sep 20;40(12):111399. PMID: 36130517.

• Goldsmith JA, DiVenere AM, Maynard JA, McLellan JS. Structural basis for non- canonical integrin engagement by Bordetella adenylate cyclase toxin. Cell Rep. 2022 Aug 16;40(7):111196. 6. PMID: 35977491; PMCID: PMC9416875.

• Rappazzo CG, Hsieh CL, Rush SA, Esterman ES, Delgado T, Geoghegan JC, Wec AZ, Sakharkar M, Más V, McLellan JS, Walker LM. Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. Immunity. 2022 Sep 13;55(9):1710-1724.e8. Epub 2022 Aug 8. PMID: 35944529.

• DiVenere AM, Amengor D, Silva RP, Goldsmith JA, McLellan JS, Maynard JA. Blockade of the Adenylate Cyclase Toxin Synergizes with Opsonizing Antibodies to Protect Mice against Bordetella pertussis. mBio. 2022 Aug 30;13(4):e0152722. Epub 2022 Aug 3. PMID: 35920558; PMCID: PMC9426472.

• Phung E, Chang LA, Mukhamedova M, Yang L, Nair D, Rush SA, Morabito KM, McLellan JS, Buchholz UJ, Mascola JR, Crank MC, Chen G, Graham BS, Ruckwardt TJ. Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Sci Transl Med. 2022 Jun 22;14(650):eabo5032. Epub 2022 Jun 22. PMID: 35731888.

• Cressey TN, Shareef AM, Kleiner VA, Noton SL, Byrne PO, McLellan JS, Mühlberger E, Fearns R. Distinctive features of the respiratory syncytial virus priming loop compared to other non-segmented negative strand RNA viruses. PLoS Pathog. 2022 Jun 22;18(6):e1010451. PMID: 35731802; PMCID: PMC9255747.

• Banerjee A, Huang J, Rush SA, Murray J, Gingerich AD, Royer F, Hsieh CL, Tripp RA, McLellan JS, Mousa JJ. Structural basis for ultrapotent antibody- mediated neutralization of human metapneumovirus. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2203326119. Epub 2022 Jun 13. PMID: 35696580; PMCID: PMC9231621.

• CL Hsieh, JS McLellan. Protein engineering responses to the COVID-19 pandemic. Current Opinion in Structural Biology, 102385. June 2022 edition.

• AD Dang, TD Vu, HH Vu, AT Van Pham, MTN Dang, B Van Le, TH Duong, ... JS McLellan, ... Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1 …Vaccine. May 14, 2022. (In press, corrected proof).

• EE Escobar, S Wang, R Goswami, MB Lanzillotti, L Li, JS McLellan, ... Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry. Analytical Chemistry. April 7, 2022.

• SA Rush, G Brar, CL Hsieh, E Chautard, JN Rainho-Tomko, C Slade, ... JS McLellan. Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus. bioRxiv. March 29, 2022.

• TN Cressey, AM Shareef, VA Kleiner, SL Noton, PO Byrne, JS McLellan, ... DISTINCTIVE FEATURES OF THE RESPIRATORY SYNCYTIAL VIRUS PRIMING LOOP COMPARED TO OTHER NON-SEGMENTED NEGATIVE STRAND RNA VIRUSES. bioRxiv. March 18, 2022.

• A Banerjee, J Huang, S Rush, J Murray, AD Gingerich, F Royer, CL Hsieh, ... JS McLellan, ... Structural basis for ultrapotent neutralization of human metapneumovirus. bioRxiv. March 14, 2022.

• CL Hsieh, SA Rush, C Palomo, CW Chou, W Pickens, V Más, JS McLellan. Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. Nature communications 13 (1), 1-11. March 14, 2022.

• D Wrapp, X Ye, Z Ku, H Su, HG Jones, N Wang, AK Mishra, DC Freed, ... JS McLellan. Structural basis for HCMV Pentamer recognition by neuropilin 2 and neutralizing antibodies. Science advances 8 (10), eabm2546. March 11, 2022.

• AR Shiakolas, KJ Kramer, NV Johnson, SC Wall, N Suryadevara, ... JS McLellan... Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking. Nature Biotechnology, 1-6. March 3, 2022.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, CL Hsieh, ... JS McLellan. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nature Structural & Molecular Biology 29 (3), 229-238. March 2, 2022.

• P Pitisuttithum, V Luvira, S Lawpoolsri, S Muangnoicharoen, JA Maynard, JS McLellan, JE Pak, S Marqusee. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase … EClinicalMedicine 45, 101323. March 1, 2022.

• SR Shoemaker, SM Costello, HT Hobbs, AW Nguyen, CL Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike protein reversibly samples an open-trimer conformation exposing novel epitopes. Biophysical Journal 121 (3), 29a. February 22, 2022

• H Chawla, SE Jossi, SE Faustini, F Samsudin, JD Allen, Y Watanabe, ML Newby, E Marcial-Juárez, RE Lamerton, JS McLellan, PJ Bond, AG Richter, AF Cunningham, M Crispin. Glycosylation and serological reactivity of an expression-enhanced SARS-CoV-2 viral spike mimetic. Journal of molecular biology 434 (2), 167332. January 30, 2022.

• JA Jenks, S Amin, A Kumar, MR Sponholtz, D Wrapp, S Venkatayogi, J Tu, ... JS McLellan ...A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus. bioRxiv. January 21, 2022.

2021 Research:

• EAF Simões, E Forleo-Neto, GP Geba, M Kamal, F Yang, H Cicirello, MR Houghton, R Rideman, Q Zhao, SL Benvin, A Hawes, ED Fuller, E Wloga, JM Novoa Pizarro, FM Munoz, SA Rush, JS McLellan, L Lipsich, N Stahl, GD Yancopoulos, DM Weinreich, CA Kyratsous, S Sivapalasingam. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clinical Infectious Diseases 73 (11), e4400-e4408. December 1, 2021.

• AK Mishra, J Hellert, N Freitas, P Guardado-Calvo, A Haouz, JM Fels, DP Maurer, DM Abelson, ZA Bornholdt, LM Walker, K Chandran, F-L Cosset, JS McLellan, FA Rey. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. Science, eabl6502. November 18, 2021.

• C-L Hsieh, AP Werner, SR Leist, et al with BS Graham, KS Corbett, JS McLellan. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports.November 2, 2021.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, J Kang, D Dayal, P Martin, RP Nowak, A-C Villani, C-L Hsieh, NC Charland, ALK Gonye, I Gushterova, HK Khanna, TJ LaSalle, KM Lavin-Parsons, BM Lilley, CL Lodenstein, K Manakongtreecheep, JD Margolin, BN McKaig, M Rojas-Lopez, BC Russo, N Sharma, J Tantivit, MF Thomas, M Sade-Feldman, J Feldman, B Julg, EJ Nilles, ER Musk, AS Menon, ES Fischer, JS McLellan, A Schmidt, MB Goldberg, MR Filbin, N Hacohen, DA Lauffenburger, G Alter. Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology 6 (64), eabj2901. October 15, 2021.

• JM Schaub, C-W Chou, H-C Kuo, K Javanmardi, C-L Hsieh,  JA Goldsmith, AM DiVenere, KC Le, D Wrapp, PO Byrne, CK Hjorth, NV Johnson, J Ludes-Meyers, AW Nguyen, N Wang, JJ Lavinder, GC Ippolito, JA Maynard, JS McLellan, IJ Finkelstein. Expression and characterization of SARS-CoV-2 spike protein. Nature Protocols. October 5, 2021.

• KJ Kramer, NV Johnson, AR Shiakolas, et al with  JE Crowe Jr, A Bukreyev, RH Carnahan, JS McLellan, IS Georgiev. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports. October 5, 2021.

• D Haslwanter, ME Dieterle, AZ Wec, CM O’Brien, M Sakharka, C Florez, K Tong, CG Rappazzo, G Lasso, O Vergnolle, AS Wirchnianski, RH Bortz II, E Laudermilch, JM Fels, A Mengotto, RJ Malonis, GI Georgiev, JA Quiroz, D Wrapp, N Wang, KE Dye, J Barnhill, JM Dye, JS McLellan, JP Daily, JR Lai, AS Herbert, LM Walker, K Chandran, and RK Jangra. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. mBio. October 5, 2021.

• J Goldsmith, AM DiVenere, JA Maynard, JS McLellan. Structural basis for antibody binding to adenylate cyclase toxin reveals RTX-linkers as key neutralization-sensitive epitopes. Plos Pathogens 17(9): e1009920. September 21, 2021.

• E Andreano, G Piccini, D Licastro, L Casalino, NV Johnson, I Paciello, S Dal Monego, E Pantano, N Manganaro, A Manenti, R Manna, E Casa, I Hyseni, L Benincasa, E Montomoli, RE Amaro, JS McLellan, and R Rappuoli. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. PNAS. 118 (36) e2103154118. September 7, 2021.

• Y Huang, AW Nguyen, C-L Hsieh,  R Silva, OS Olaluwoye, RE Wilen, TS Kaoud, LR Azouz, AN Qerqez, KC Le, AL Bohanon,AM DiVenere, Y Liu, AG Lee, D Amengor, KN Dalby, y S D’Arc, JS McLellan, JA Maynard. Identification of a conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses. bioRxiv 2021.01.31.428824.  (Preprint). Commentary [link] August 20, 2021.

• S Kaur, J Gomez-Blanco, A Khalifa, S Adinarayanan, R Sanchez-Garcia, D Wrapp, JS McLellan, KH Bui, J Vargas. Local methods to improve cryo-electron microcopy maps. Computational Optical Sensing and Imaging, CTu4B. 3. July 19, 2021.

• SM Costello, SR Shoemaker, HT Hobbs, AW Nguyen, C-L Hsieh, JA Maynard, JS McLellan, JE Pak, S Marqusee. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. bioRxiv 2021.07.11.451855; (Preprint). July 11, 2021.

• X Wang, Z Du, KE Johnson, RF Pasco, SJ Fox, M Lachmann, JS McLellan, and LA Meyers. Effects of COVID-19 Vaccination Timing and Risk Prioritization on Mortality Rates, United States. Emerging Infectious Diseases. Volume 27, Number 7—July 2021.

• WN Voss, YJ Hou, NV Johnson, G Delidakis, JE Kim , K Javanmardi, AP Horton, F Bartzoka, CJ Paresi, Y Tanno, C-W Chou, SA Abbasi, W Pickens, K George, DR Boutz, DM Towers, JR McDaniel, D Billick, J Goike, L Rowe, D Batra, J Pohl, J Lee, S Gangappa, S Sambhara, M Gadush, N Wang, MD Person, BL Iverson, JD Gollihar, J Dye , A Herbert, IJ Finkelstein, RS Baric, JS McLellan, G Georgiou, JJ Lavinder, GC Ippolito. Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes. Science. 372(6546):1108-1112. PMID: 33947773. June 4, 2021. 

• AR Shiakolas, KJ Kramer, Dl Wrapp, SI Richardson, A Schäfer, S Wall, N Wang, K Janowska, KA Pilewski, R Venkat, R Parks, NP Manamela, N Raju, E Friedman Fechter, CM Holt, N Suryadevara, RE Chen, DR Martinez, RS Nargi, RE Sutton, JE Ledgerwood, BS Graham, MS Diamond, BF Haynes, P Acharya, RH Carnahan, JE Crowe Jr, RS Baric, L Morris, JS McLellan, IS Georgie. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine 2 (6), 100313. June 2021.

• T Li, W Xue, Q Zheng, S Song, C Yang, HL Xiong, S Zhang, M Hong, YL Zhang, H Yu, Y Zhang, H Sun, Y Huang, T Deng, X Chi, J Li, S Wang, L Zhou, T Chen, Y Wang, T Cheng, T-Y Zhang, Q Yuan, Q Zhao, J Zhang, J McLellan, Z Hong Zhou, Z Zhang, Y Gu, S Li, N Xia. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist to circulating variants. Research Square (Preprint). June 2021.

• JM Fels, DP Maurer, AS Herbert, AS Wirchnianski, O Vergnolle, RW Cross, DM Abelson, CL Moyer, AK Mishra, JT Aguilan, AI Kuehne, NT Pauli, RR Bakken, EK Nyakatura, J Hellert, G Quevedo, L Lobel, S Balinandi, JJ Lutwama, L Zeitlin, TW Geisbert, FA Rey, S Sidoli, JS McLellan, JR Lai, ZA Bornholdt, JM Dye, LM Walker, K Chandran. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell. June 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ... McLellan, JS, ... Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature 594 (7862), 253-258. June 2021.

• TE Sztain, S-H Ahn, et. al with JS McLellan. A glycan gate controls opening of the SARS-CoV-2 spike protein. bioRxiv 2021.02.15.431212. May 17, 2021.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... McLellan, JS, ... The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Science translational medicine 13 (593). May 12, 2021.

• I Rossey, CL Hsieh, K Sedeyn, M Ballegeer, B Schepens, JS McLellan, ... A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody. Journal of Virology 95 (11), e02279-20. May 10, 2021.

• LM Stephens, KA Ross, KA Waldstein, KL Legge, JS McLellan, ... Prefusion F–Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus. The Journal of Immunology 206 (9), 2122-2134. May 1, 2021.

• L Stephens, KA Ross, KL Legge, JS McLellan, B Narasimhan, SM Varga. Prefusion F-based polyanhydride nanovaccine induces robust humoral and cell-mediated immunity resulting in long-lasting protection against respiratory syncytial virus. The Journal of Immunology 206 (1 Supplement), 59.04-59.042021. May 1, 2021.

• M Mukhamedova, D Wrapp, CH Shen, MSA Gilman, TJ Ruckwardt, CA Schramm, L Ault L, L Chang, A Derrien-Colemyn, SAM Lucas, A Ransier, S Darko, E Phung, L Wang, Y Zhang, SA Rush, B Madan B, GBE Stewart-Jones, PJ Costner, LA Holman, SP Hickman, NM Berkowitz, NA Doria-Rose, KM Morabito, BJ DeKosky, MR Gaudinski, GL Chen, MC Crank, J Misasi, NJ Sullivan, DC Douek, PD Kwong, BS Graham, JS McLellan, JR Mascola. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity. 54(4):769-780.e6. April 13, 2021.

• GS Cockerill, RM Angell, A Bedernjak, I Chuckowree, I Fraser, ... JS McLellan, ... Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. Journal of Medicinal Chemistry 64 (7), 3658-3676. March 17, 2021.

• S Kaur, J Gomez-Blanco, AAZ Khalifa, S Adinarayanan, ... JS McLellan, ... Local computational methods to improve the interpretability and analysis of cryo-EM maps. Nature communications 12 (1), 1-12. 2021. February 23, 2021.

• M Sakharkar, CG Rappazzo, WF Wieland-Alter, CL Hsieh, D Wrapp, ... JS McLellan, ... Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science immunology 6 (56). February 23, 2021.

• CG Rappazzo, et. al with J McLellan. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. January 25, 2021.

• Z Ku, X Xie, E Davidson, X Ye, H Su, VD Menachery, Y Li, Z Yuan, ...JS McLellan, ... Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nature communications 12 (1), 1-13. Janurary 20, 2021.

• X Wang, Z Du, KE Johnson, SJ Fox, M Lachmann, JS McLellan, LA Meyers. The impacts of COVID-19 vaccine timing, number of doses, and risk prioritization on mortality in the US. medRxiv. January 18, 2021.

• BL Innis, LD Mercer, JA White, R Scharf, R Hjorth, S Lamola, ...JS McLellan, ... Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase … medRxiv. January 1, 2021.

• NM Shaban, R Yan, K Shi, SN Moraes, AZ Cheng, MA Carpenter, ... JS McLellan, ...CryoEM structure of the EBV ribonucleotide reductase BORF2 and mechanism of APOBEC3B inhibition. bioRxiv. January 1, 2021.

• AR Shiakolas, N Johnson, KJ Kramer, N Suryadevara, D Wrapp, ... JS McLellan, ... Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking. bioRxiv. January 1, 2021.

• P Kaplonek, C Wang, Y Bartsch, S Fischinger, MJ Gorman, K Bowman, ...JS McLellan, ... Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19. bioRxiv. January 1, 2021.

• JD Gollihar, JS McLellan, DR Boutz, J Goike, A Horton, EC Gardner, ... Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality. bioRxiv. January 1, 2021.

• D Wrapp, X Ye, Z Ku, H Su, HG Jones, N Wang, AK Mishra, DC Freed, ...JS McLellan. Structural basis for HCMV Pentamer recognition by antibodies and neuropilin 2. bioRxiv. 2021.January 1, 2021.

• AC Walls, MC Miranda, MN Pham, A Schaefer, A Greaney, ... JS McLellan, ...Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. bioRxiv. January 1, 2021.

• PS Arunachalam, AC Walls, N Golden, C Atyeo, S Fischinger, C Li, P Aye, ...JS McLellan, ...Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv. January 1, 2021.

2020 Research:

• P Pino, J Kint, D Kiseljak, V Agnolon, G Corradin, AV Kajava, P Rovero, ... JS McLellan, ... Trimeric SARS-CoV-2 spike proteins produced from CHO cells in bioreactors are high-quality antigens. Processes 8 (12), 1539. November 25, 2020.

• R Melero, COS Sorzano, B Foster, JL Vilas, M Martínez, R Marabini, ... JS McLellan, ... Continuous flexibility analysis of SARS-CoV-2 Spike prefusion structures. IUCrJ 7 (6). November 1, 2020.

• L Casalino, Z Gaieb, JA Goldsmith, CK Hjorth, AC Dommer, AM Harbison, ... JS McLellan, ... Beyond shielding: the roles of glycans in the SARS-CoV-2 spike protein, ACS Central Science 6 (10), 1722-1734. September 23, 2020.

• SW Long, et. al. with J Gollihar, JS. McLellan, C-W Chou, K Javanmardi, IJ. Finkelstein, James M. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. medRxiv. September 22, 2020.

• X Ye, H Su, D Wrapp, DC Freed, F Li, Z Yuan, A Tang, L Li, Z Ku, W Xiong, ...JS McLellan, ... Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step. PLoS pathogens 16 (8), e1008736. August, 17, 2020.

• KS Corbett, DK Edwards, SR Leist, OM Abiona, S Boyoglu-Barnum, ... JS McLellan, ... SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586 (7830), 567-571. August 5, 2020.

• C-l Hsieh, JA Goldsmith, et. al (J Lavinder, G Ipplito, J Maynard, I Finkelstein and J McLellan). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. July 23, 2020.

• AZ Wec, D Wrapp, et. al., with JS McLellan. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science. June 15, 2020. 

• RJ Loomis, GBE Stewart-Jones, Y Tsybovsky, RT Caringal, KM Morabito, ... JS McLellan ...Structure-based design of Nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development. Frontiers in immunology 11, 842. June 11, 2020.

• Y Watanabe, ZT Berndsen, J Raghwani, GE Seabright, JD Allen, ...  JS McLellan ...Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. Nature communications 11 (1), 1-10. May 27, 2020.

• T Smith, A Patel, S Ramos, et al. with J McLellan. Immunogenicity of a DNA vaccine candidate for COVID-19. Nature communications 11, 260. May 20, 2020.

• AZ Wec, D Wrapp, AS Herbert, D Maurer, D Haslwanter, M Sakharkar, ... JS McLellan,... Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein. bioRxiv. May 16, 2020.

• S Vendeville, A Tahri, L Hu, S Demin, L Cooymans, A Vos, L Kwanten, ... JS McLellan ... Discovery of 3-({5-Chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl}methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one (JNJ-53718678), a … Journal of medicinal chemistry 63 (15), 8046-8058. May 14, 2020.

• JH Choi, HM Woo, T Lee, S Lee, SM Shim, WJ Park, JS Yang, JA Kim, ... JS McLellan ... Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS One 15 (5), e0232757. May 8, 2020.

• D Wrapp, D De Vlieger, KS. Corbett, GM Torres, N Wang, W Van Breedam, K Roose, L van Schie, VIB-CMB COVID-19 Response Team, M Hoffmann, S Pöhlmann, BS Graham, N Callewaert, B Schepens, X Saelens, and JS McLellan. Structural Basis for Potent Neutralization of Betacoronaviruses. Cell. May 5, 2020.

• CS Nelson, JA Jenks, N Pardi, M Goodwin, H Roark, W Edwards, ... JS McLellan ... Human cytomegalovirus glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunization. Journal of virology 94 (9), e00186-20. April 16, 2020.

• L Rutten, MSA Gilman, S Blokland, J Juraszek, JS McLellan ...Structure-based design of prefusion-stabilized filovirus glycoprotein trimers. Cell reports 30 (13), 4540-4550. e3. March 31, 2020.

• AK Mishra, CL Moyer, DM Abelson, DJ Deer, K El Omari, R Duman, ... JS McLellan ...Structure and characterization of Crimean-Congo hemorrhagic fever virus GP38. Journal of virology 94 (8), e02005-19. March 31, 2020.

• Y Watanabe, JD Allen, D Wrapp, JS McLellan, M Crispin. Site-specific analysis of the SARS-CoV-2 glycan shield. March 28, 2020.

• D Wrapp, N Wang, KS Corbett, JA Goldsmith, C-Lin Hsieh, O Abiona, BS Graham, JS McLellan. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 1260-1263. March 13, 2020

• TRF Smith, A Patel, S Ramos, D Elwood, X Zhu, J Yan, M Yang, ... JS McLellan,... Rapid development of a synthetic DNA vaccine for COVID-19. Nature Communication 11, Article number: 2601. March 3, 2020.

• AR Shiakolas, KJ Kramer, D Wrapp, SI Richardson, A Schäfer, S Wall, ... JS McLellan,... Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. bioRxiv. January 1, 2020.

• CG Rappazzo, VT Longping, CI Kaku, D Wrapp, M Sakharkar, D Huang, ... JS McLellan,...  An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19. bioRxiv. January 1, 2020.

• BE Jones, PL Brown-Augsburger, KS Corbett, K Westerndorf, J Davies, ... JS McLellan,... LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. January 1, 2020.